BRPI0920112A2 - derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento. - Google Patents

derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento.

Info

Publication number: BRPI0920112A2
Authority: BR; Brazil
Prior art keywords: medicament; production; cdk inhibitors; anilinopyrimidine derivatives; sulfoximine substituted
Prior art date: 2008-10-21

Application number

BRPI0920112A

Other languages

English (en)

Inventor

Gerhard Siemeister

Julia Schulze

Philip Lienau

Rolf Jautelat

Ulrich Lücking

Original Assignee

Bayer Schering Pharma Akltiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-21

Filing date

2009-10-09

Publication date

2015-12-22

2009-10-09 Application filed by Bayer Schering Pharma Akltiengesellschaft filed Critical Bayer Schering Pharma Akltiengesellschaft

2015-12-22 Publication of BRPI0920112A2 publication Critical patent/BRPI0920112A2/pt

Links

150000008059 anilinopyrimidines Chemical class 0.000 title 1
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
125000005555 sulfoximide group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0920112A 2008-10-21 2009-10-09 derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento. BRPI0920112A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08167113A EP2179991A1 (de)	2008-10-21	2008-10-21	Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007247 WO2010046035A1 (de)	2008-10-21	2009-10-09	Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel

Publications (1)

Publication Number	Publication Date
BRPI0920112A2 true BRPI0920112A2 (pt)	2015-12-22

Family

ID=40282208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920112A BRPI0920112A2 (pt)	2008-10-21	2009-10-09	derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento.

Country Status (38)

Country	Link
US (1)	US8735412B2 (pt)
EP (2)	EP2179991A1 (pt)
JP (1)	JP5564054B2 (pt)
KR (1)	KR20110069115A (pt)
CN (1)	CN102197029B (pt)
AR (1)	AR074053A1 (pt)
AU (1)	AU2009306733C1 (pt)
BR (1)	BRPI0920112A2 (pt)
CA (1)	CA2739739C (pt)
CO (1)	CO6361926A2 (pt)
CR (1)	CR20110210A (pt)
CU (1)	CU24052B1 (pt)
CY (1)	CY1115590T1 (pt)
DK (1)	DK2350026T3 (pt)
DO (1)	DOP2011000107A (pt)
EA (1)	EA019230B1 (pt)
EC (1)	ECSP11010992A (pt)
ES (1)	ES2499028T3 (pt)
HN (1)	HN2011001019A (pt)
HR (1)	HRP20140830T1 (pt)
IL (1)	IL211713A (pt)
MA (1)	MA32723B1 (pt)
MX (1)	MX2011004238A (pt)
MY (1)	MY155230A (pt)
NZ (1)	NZ592314A (pt)
PA (1)	PA8846201A1 (pt)
PE (1)	PE20110546A1 (pt)
PL (1)	PL2350026T3 (pt)
PT (1)	PT2350026E (pt)
RS (1)	RS53523B1 (pt)
SA (1)	SA109300632B1 (pt)
SI (1)	SI2350026T1 (pt)
TN (1)	TN2011000199A1 (pt)
TW (2)	TWI458716B (pt)
UA (1)	UA103500C2 (pt)
UY (1)	UY32190A (pt)
WO (1)	WO2010046035A1 (pt)
ZA (1)	ZA201103727B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en)	2009-08-14	2011-02-17	Boehringer Ingelheim International Gmbh	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
DE102010014426A1 (de) *	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de)	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) *	2010-09-23	2012-03-29	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TWI555737B (zh)	2011-05-24	2016-11-01	拜耳知識產權公司	含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080991A1 (de)	2011-08-16	2013-02-21	Bayer Pharma AG	Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) *	2011-08-16	2013-02-21	Bayer Pharma AG	Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
JP5976814B2 (ja)	2011-09-16	2016-08-24	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
WO2013139734A1 (de) *	2012-03-21	2013-09-26	Bayer Intellectual Property Gmbh	Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore
CA2964696C (en) *	2014-10-16	2022-09-06	Bayer Pharma Aktiengesellschaft	Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
EP3849537B1 (en)	2018-09-10	2024-10-23	Mirati Therapeutics, Inc.	Combination therapies
US12441707B2 (en)	2019-12-30	2025-10-14	Tyra Biosciences, Inc.	Indazole compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4029650A1 (de)	1990-09-19	1992-03-26	Hoechst Ag	2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en)	1997-07-12	2005-12-07	Cancer Research Technology Limited	Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en)	1997-10-15	2002-08-27	Krenitsky Pharmaceuticals, Inc.	Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6632820B1 (en)	1998-08-29	2003-10-14	Astrazeneca Ab	Pyrimidine compounds
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
BR0209774A (pt)	2001-05-29	2004-06-01	Schering Ag	Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
EP1483260A1 (de) *	2002-03-11	2004-12-08	Schering Aktiengesellschaft	Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
JP2006508997A (ja)	2002-11-28	2006-03-16	シエーリングアクチエンゲゼルシャフト	Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
DE10349423A1 (de)	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1794134A1 (de) *	2004-09-29	2007-06-13	Bayer Schering Pharma Aktiengesellschaft	Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de)	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de)	2006-06-08	2007-12-13	Bayer Schering Pharma Ag	Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) *	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

2008
- 2008-10-21 EP EP08167113A patent/EP2179991A1/de not_active Withdrawn
2009
- 2009-10-09 PE PE2011000917A patent/PE20110546A1/es not_active Application Discontinuation
- 2009-10-09 BR BRPI0920112A patent/BRPI0920112A2/pt not_active IP Right Cessation
- 2009-10-09 SI SI200931004T patent/SI2350026T1/sl unknown
- 2009-10-09 KR KR1020117009024A patent/KR20110069115A/ko not_active Abandoned
- 2009-10-09 DK DK09778874.9T patent/DK2350026T3/da active
- 2009-10-09 ES ES09778874.9T patent/ES2499028T3/es active Active
- 2009-10-09 CA CA2739739A patent/CA2739739C/en not_active Expired - Fee Related
- 2009-10-09 WO PCT/EP2009/007247 patent/WO2010046035A1/de not_active Ceased
- 2009-10-09 EP EP09778874.9A patent/EP2350026B1/de active Active
- 2009-10-09 PL PL09778874T patent/PL2350026T3/pl unknown
- 2009-10-09 MX MX2011004238A patent/MX2011004238A/es active IP Right Grant
- 2009-10-09 PT PT97788749T patent/PT2350026E/pt unknown
- 2009-10-09 HR HRP20140830AT patent/HRP20140830T1/hr unknown
- 2009-10-09 RS RSP20140466 patent/RS53523B1/sr unknown
- 2009-10-09 NZ NZ592314A patent/NZ592314A/xx not_active IP Right Cessation
- 2009-10-09 UA UAA201106183A patent/UA103500C2/uk unknown
- 2009-10-09 AU AU2009306733A patent/AU2009306733C1/en not_active Ceased
- 2009-10-09 JP JP2011532519A patent/JP5564054B2/ja not_active Expired - Fee Related
- 2009-10-09 CN CN200980141978.7A patent/CN102197029B/zh not_active Expired - Fee Related
- 2009-10-09 MY MYPI2011001632A patent/MY155230A/en unknown
- 2009-10-09 EA EA201100623A patent/EA019230B1/ru not_active IP Right Cessation
- 2009-10-09 US US13/125,066 patent/US8735412B2/en not_active Expired - Fee Related
- 2009-10-19 PA PA20098846201A patent/PA8846201A1/es unknown
- 2009-10-20 SA SA109300632A patent/SA109300632B1/ar unknown
- 2009-10-20 UY UY0001032190A patent/UY32190A/es not_active Application Discontinuation
- 2009-10-21 TW TW098135674A patent/TWI458716B/zh not_active IP Right Cessation
- 2009-10-21 AR ARP090104043A patent/AR074053A1/es not_active Application Discontinuation
- 2009-10-21 TW TW103126302A patent/TWI496774B/zh not_active IP Right Cessation
2011
- 2011-03-14 IL IL211713A patent/IL211713A/en not_active IP Right Cessation
- 2011-04-15 HN HN2011001019A patent/HN2011001019A/es unknown
- 2011-04-20 EC EC2011010992A patent/ECSP11010992A/es unknown
- 2011-04-20 TN TN2011000199A patent/TN2011000199A1/fr unknown
- 2011-04-20 CU CU2011000088A patent/CU24052B1/es active IP Right Grant
- 2011-04-20 MA MA33786A patent/MA32723B1/fr unknown
- 2011-04-20 CO CO11049624A patent/CO6361926A2/es active IP Right Grant
- 2011-04-20 DO DO2011000107A patent/DOP2011000107A/es unknown
- 2011-04-25 CR CR20110210A patent/CR20110210A/es unknown
- 2011-05-20 ZA ZA2011/03727A patent/ZA201103727B/en unknown
2014
- 2014-09-05 CY CY20141100717T patent/CY1115590T1/el unknown

Also Published As

Publication number	Publication date
PE20110546A1 (es)	2011-08-12
AR074053A1 (es)	2010-12-22
CA2739739C (en)	2016-12-20
EP2179991A1 (de)	2010-04-28
EA201100623A1 (ru)	2011-12-30
RS53523B1 (sr)	2015-02-27
SA109300632B1 (ar)	2013-07-04
CA2739739A1 (en)	2010-04-29
CU20110088A7 (es)	2011-12-28
MY155230A (en)	2015-09-30
HN2011001019A (es)	2013-07-01
JP5564054B2 (ja)	2014-07-30
TW201444803A (zh)	2014-12-01
CY1115590T1 (el)	2017-01-04
HRP20140830T1 (hr)	2014-11-21
TW201020237A (en)	2010-06-01
MX2011004238A (es)	2011-05-23
CN102197029A (zh)	2011-09-21
AU2009306733A1 (en)	2010-04-29
US8735412B2 (en)	2014-05-27
PT2350026E (pt)	2014-09-12
IL211713A0 (en)	2011-06-30
AU2009306733C1 (en)	2016-07-14
ES2499028T3 (es)	2014-09-26
ECSP11010992A (es)	2011-05-31
CO6361926A2 (es)	2012-01-20
WO2010046035A1 (de)	2010-04-29
CU24052B1 (es)	2014-12-26
TWI458716B (zh)	2014-11-01
CN102197029B (zh)	2014-05-14
EP2350026B1 (de)	2014-06-18
AU2009306733B2 (en)	2015-11-12
TN2011000199A1 (en)	2012-12-17
TWI496774B (zh)	2015-08-21
US20110294838A1 (en)	2011-12-01
DK2350026T3 (da)	2014-09-15
UA103500C2 (uk)	2013-10-25
ZA201103727B (en)	2014-11-26
PL2350026T3 (pl)	2014-11-28
KR20110069115A (ko)	2011-06-22
IL211713A (en)	2015-04-30
UY32190A (es)	2010-05-31
EA019230B1 (ru)	2014-02-28
SI2350026T1 (sl)	2014-10-30
PA8846201A1 (es)	2010-05-26
CR20110210A (es)	2011-06-08
NZ592314A (en)	2013-02-22
EP2350026A1 (de)	2011-08-03
JP2012506391A (ja)	2012-03-15
MA32723B1 (fr)	2011-10-02
DOP2011000107A (es)	2011-05-15

Legal Events

Date	Code	Title	Description
2016-10-25	B25D	Requested change of name of applicant approved	Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)
2016-11-29	B25A	Requested transfer of rights approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)
2017-08-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-11-28	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Publication	Publication Date	Title
BRPI0920112A2 (pt)	2015-12-22	derivados de anilinopirimidina substituídos com sulfoximina como inibidores cdk, sua produção e uso como medicamento.
BRPI1012892A2 (pt)	2018-03-13	composto, e, composição farmacêutica.
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0815773A2 (pt)	2019-09-24	composto, e, medicamento.
BRPI0923828A2 (pt)	2019-09-24	método de produção de isopreno e um co-produto.
BRPI0813455A2 (pt)	2014-12-23	Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI0914802A2 (pt)	2015-08-11	Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
CR10328A (es)	2008-11-18	Compuestos organicos
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI1014583A2 (pt)	2016-04-26	sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo.
BRPI1016117A2 (pt)	2016-04-12	derivados de isoxazol-isoxazol e isoxasol-isotiazol.
BRPI0915552A2 (pt)	2017-06-20	derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
BRPI0919807A2 (pt)	2015-12-22	compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI1015943A8 (pt)	2018-01-09	derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
DK2442870T3 (da)	2014-06-30	Pyrazinooxazepin-derivater.
BRPI1016192A2 (pt)	2016-04-19	derivados de soxazol.
BRPI1014125A2 (pt)	2016-04-12	composto, composição farmacêutica, e, uso de um composto.
BRPI0907486A2 (pt)	2015-07-14	Triazolpiridazinas como inibidores de par1, sua produção e uso como medicamentos
BRPI0906727A2 (pt)	2015-08-04	Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
BRPI0816679A2 (pt)	2015-03-17	Derivados de ftalazinona.
BRPI0819202A2 (pt)	2015-05-05	Derivado heterocíclico, e, composição farmacêutica
BR112012014459A2 (pt)	2017-03-07	derivados de pirrolidina.
EP2397150A4 (en)	2012-08-29	BIOPOLYMER, IMPLANT WITH IT AND USE